Edinburgh healthtech firm Manus Neurodynamica nets six-figure funding

An Edinburgh-based company whose technology can help diagnose Parkinson’s disease and other movement disorders has closed a £750,000 financing round.

The firm's NeuroMotor Pen captures and analyses limb and hand movements. Picture: The Bigger Picture Agency.

Manus Neurodynamica said the round was led by Par Equity with support from the Scottish Investment Bank (SIB), and Old College Capital, the University of Edinburgh’s venture fund. It marks the third investment Par Equity has made since its recent partnership with British Business Investments through the Regional Angels Programme.

The investment will allow Manus to grow the team to support the commercial rollout into the global clinical and clinical trials markets, to add new clinical indications and to develop the next generation of products. Its NeuroMotor Pen captures and analyses “the slightest” limb and hand movements, giving medics “a non-invasive, early detection and monitoring tool kit”.

Sign up to our daily newsletter

The i newsletter cut through the noise

Read More

Read More
Fife life sciences firm Pneumagen nets £4m to develop product to tackle Covid-19
Rutger Zietsma, CEO of Manus Neurodynamica. Picture: The Bigger Picture Agency.

Chief executive Rutger Zietsma said: “We are excited to be working with Par Equity and our other new shareholders to accelerate the commercialisation of our neuromotor assessment technology. From our very first meeting it was obvious that we and Par Equity shared a vision of the global potential for the product, not just in Parkinson’s disease but in many other clinical indications.”

SIB director Kerry Sharp commented: “Manus Neurodynamica has enjoyed positive outcomes in clinical trials at home and internationally, and we are happy to provide continued support to the company through the next stage of its growth plans.”


Meanwhile, Alva-based medical testing company Omega Diagnostics has welcomed major progress by the consortium in which it is involved on developing a Covid-19 lateral flow antibody test that can be used at home.

The life sciences firm had noted in April that it had signed a memorandum of understanding with Abingdon Health, BBI Solutions, and CIGA Healthcare, in conjunction with the University of Oxford to form the UK-Rapid Test Consortium to jointly develop and manufacture a Covid-19 Rapid Test as part of the UK government’s five pillar national testing strategy.

Omega yesterday praised the “significant” progress made to date in such a short period of time, with “design freeze” on the test expected in June. After that the Scottish firm will provide volume manufacturing capacity of the test.

Chief executive Colin King said: “Everyone is working extremely hard to deliver a high-quality product as soon as possible to help play a part in returning life back to more normal levels in the UK.”

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.With the coronavirus lockdown having a major impact on many of our advertisers - and consequently the revenue we receive - we are more reliant than ever on you taking out a digital subscription.Subscribe to scotsman.com and enjoy unlimited access to Scottish news and information online and on our app. With a digital subscription, you can read more than 5 articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit https://www.scotsman.com/subscriptions now to sign up.

Our journalism costs money and we rely on advertising, print and digital revenues to help to support them. By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Joy Yates

Editorial Director


Want to join the conversation? Please or to comment on this article.